Zydus Lifesciences surges as its arm signs exclusive licensing, supply agreement with MSN Laboratories
Zydus Lifesciences is currently trading at Rs. 1024.20, up by 15.50 points or 1.54% from its previous closing of Rs. 1008.70 on the BSE.
The scrip opened at Rs. 1016.05 and has touched a high and low of Rs. 1026.05 and Rs. 1011.00 respectively. So far 5360 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1033.15 on 07-May-2024 and a 52 week low of Rs. 482.55 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1026.05 and Rs. 970.45 respectively. The current market cap of the company is Rs. 101498.82 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.35% and 6.66% respectively.
Zydus Lifesciences’ wholly owned subsidiary -- Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market.
As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the Product in the US market. MSN was a first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
